Clinical Trials Logo

Overweight or Obesity clinical trials

View clinical trials related to Overweight or Obesity.

Filter by:

NCT ID: NCT06445296 Recruiting - Clinical trials for Overweight or Obesity

Postprandial Effects of Animal Versus Plant-Based Protein

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Shifting away from diets high in animal products towards more plant predominant diets is recommended by many health organizations to both reduce the negative environmental impacts of animal agriculture and to improve health outcomes. As a result, a number of plant-based meat alternatives such as Beyond Meat have been formulated to promote increased plant consumption. However, evidence is limited on the impact of newer plant-based meat alternatives on common cardiometabolic risk factors. The investigators aim to compare the acute metabolic, gastrointestinal, and inflammatory effects of a plant-based meat alternative (i.e., Beyond Meat) versus a comparable beef product within the context of high-fat, "Western-style" meal (i.e., eggs, meat, refined bread product). The investigators will also examine whether these responses differ based on whether individuals have a normal-weight or have overweight/obesity.

NCT ID: NCT06426693 Not yet recruiting - Clinical trials for Overweight or Obesity

Craving Network Neurofeedback

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This project tests whether individuals with overweight or obesity and high craving can learn to change their brain response to food cues using neurofeedback, to impact their craving and eating behavior.

NCT ID: NCT06396429 Recruiting - Clinical trials for Overweight or Obesity

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Start date: May 13, 2024
Phase: Phase 3
Study type: Interventional

The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.

NCT ID: NCT06383442 Completed - Clinical trials for Overweight or Obesity

HIIT on Overweight Middle-aged Adults

HIIT
Start date: May 25, 2021
Phase: N/A
Study type: Interventional

36 middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week) and the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss.

NCT ID: NCT06372860 Recruiting - Pregnancy Clinical Trials

DPP Feasibility Study of Breastfeeding - eMOMS 2.0

Start date: April 30, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the impact of a comprehensive intervention that combines breastfeeding support with a diabetes prevention-based program (DPP) on postpartum weight retention and lactation duration among women with pre-pregnancy overweight or obesity. This intervention, named eMOMS, is delivered by a certified health coach via a mobile health (mHealth) application.

NCT ID: NCT06371326 Enrolling by invitation - Clinical trials for Overweight or Obesity

A Study of ZT002 Injection in Participants With Overweight or Obesity

Start date: November 21, 2023
Phase: Phase 1
Study type: Interventional

This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.

NCT ID: NCT06366399 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

The Acute T-Rex (Timing of Resistance Exercise) Study

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The primary aim of this study is to evaluate if a single bout of AM vs PM resistance exercise has different effects on insulin sensitivity and sleep. A randomized cross-over trial be used to compare resistance exercise at two different times of the day. Each condition will take place in a laboratory setting. Each condition will consist of exercise, overnight sleep, and oral glucose tolerance tests the following day. The AM exercise will occur ~1.5 hours after habitual wake, and PM exercise will occur ~11 hours after habitual wake. After a 2-6 week washout, participants will complete the other condition. The hypothesis is that PM exercise will be more beneficial than AM exercise in improving insulin sensitivity. This study could identify if there is a better time of day to perform resistance exercise to decrease risk of developing Type 2 Diabetes Mellitus.

NCT ID: NCT06360536 Not yet recruiting - Clinical trials for Overweight or Obesity

Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women

OVERCOME-IT
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to collect preliminary data on the feasibility, acceptability, and potential effects of a novel, remotely delivered resistance training program.

NCT ID: NCT06305650 Recruiting - Clinical trials for Overweight or Obesity

Probiotic Influence on Obesity-Related Lipidemia

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

This study aims to investigate the effects of Bifidobacterium breve BBr60 on key health indicators in overweight and obese adults. Specifically, it will assess the probiotic's impact on body composition metrics such as BMI, body fat percentage, WHR, and BMR. The inclusion criteria for participants are a BMI of ≥28 kg/m^2, targeting individuals who stand to benefit significantly from metabolic and body composition improvements.

NCT ID: NCT06247020 Completed - Clinical trials for Glucose Metabolism Disorders

Metabolic Effects of Oral Sodium Butyrate Supplementation on Overweight Individuals

Start date: February 24, 2022
Phase: N/A
Study type: Interventional

Numerous evidences suggest an important role of short-chain fatty acids, produced by the intestinal fermentation of dietary fibers by the intestinal microbiota, in the modulation of various biological functions relevant to human health. In particular, butyrate, in addition to its trophic action on enterocytes, could improve insulin sensitivity and increase GLP-1 secretion, suggesting a possible role in the modulation of glucose metabolism. However, to date, very few randomized controlled trials (RCTs) have observed a significant increase in plasma butyrate concentrations in humans after nutritional interventions with high-fiber diets or foods. Butyrate occurs naturally in some foods, such as milk and dairy products, where it is often associated with sodium, becoming sodium butyrate. Therefore, recent studies suggest the use of oral sodium butyrate supplements in order to obtain a significant increase in butyrate plasma concentrations able to exert the potential beneficial effects related to them. To date, few studies have investigated the effect of oral sodium butyrate supplementation on glucose metabolism in healthy or overweight individuals, individuals at high cardiometabolic risk, and individuals with type 2 diabetes. Therefore, the purpose of this pilot study is to evaluate the effects of oral sodium butyrate supplementation, versus placebo, on glucose tolerance and insulin sensitivity in a group of overweight/obese individuals and the mechanisms underlying these effects.